Agenus Inc (NASDAQ:AGEN)’s Trend Unknown, Especially After Increased Shorts

June 17, 2018 - By wolcottdaily

Agenus Inc. (NASDAQ:AGEN) Logo

Investors sentiment increased to 1.46 in 2018 Q1. Its up 0.20, from 1.26 in 2017Q4. It improved, as 11 investors sold Agenus Inc. shares while 24 reduced holdings. 20 funds opened positions while 31 raised stakes. 46.47 million shares or 27.93% more from 36.32 million shares in 2017Q4 were reported.
D E Shaw & Communication Incorporated owns 1.82M shares. 2.75M are held by Artal Group Inc. Price T Rowe Associates Md reported 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Crestwood Gp Ltd has invested 0.01% in Agenus Inc. (NASDAQ:AGEN). Bluemountain Cap Lc accumulated 0% or 44,743 shares. Washington-based Fisher Asset Mngmt Ltd Liability has invested 0% in Agenus Inc. (NASDAQ:AGEN). Teacher Retirement System Of Texas has invested 0% in Agenus Inc. (NASDAQ:AGEN). Florida-based Raymond James Assocs has invested 0% in Agenus Inc. (NASDAQ:AGEN). 200 were reported by Atlantic Trust Gru Llc. United Svcs Automobile Association reported 11,520 shares stake. 10,341 were accumulated by Bluecrest Capital Limited. Gsa Cap Partners Limited Liability Partnership accumulated 0% or 13,900 shares. Federated Invsts Pa has 2,098 shares for 0% of their portfolio. Jpmorgan Chase And Com owns 0% invested in Agenus Inc. (NASDAQ:AGEN) for 15,312 shares. Sg Americas Lc owns 15,751 shares or 0% of their US portfolio.

The stock of Agenus Inc (NASDAQ:AGEN) registered an increase of 1.46% in short interest. AGEN’s total short interest was 10.35M shares in June as published by FINRA. Its up 1.46% from 10.20M shares, reported previously. With 1.56M shares average volume, it will take short sellers 7 days to cover their AGEN’s short positions. The short interest to Agenus Inc’s float is 13.15%.

The stock decreased 3.57% or $0.1 during the last trading session, reaching $2.7. About 2.18M shares traded or 49.59% up from the average. Agenus Inc. (NASDAQ:AGEN) has declined 0.29% since June 17, 2017 and is downtrending. It has underperformed by 12.86% the S&P500.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodyÂ’s immune system for patients suffering with cancer. The company has market cap of $280.80 million. The firm offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It currently has negative earnings. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.